Insider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells 6,665 Shares of Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 6,665 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $47.56, for a total transaction of $316,987.40. Following the transaction, the insider now directly owns 280,793 shares in the company, valued at $13,354,515.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, August 7th, Carl Dambkowski sold 7,335 shares of Apogee Therapeutics stock. The stock was sold at an average price of $40.67, for a total value of $298,314.45.
• On Wednesday, July 3rd, Carl Dambkowski sold 5,995 shares of Apogee Therapeutics stock. The shares were sold at an average price of $37.60, for a total value of $225,412.00.

Apogee Therapeutics Stock Performance

Shares of APGE opened at $47.25 on Friday. Apogee Therapeutics, Inc. has a 52-week low of $14.19 and a 52-week high of $72.29. The firm has a market cap of $2.76 billion, a price-to-earnings ratio of -9.00 and a beta of 2.74. The business’s fifty day moving average is $45.80 and its 200-day moving average is $48.98.

Apogee Therapeutics (NASDAQ:APGE) last released its earnings results on Monday, August 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.60). As a group, research analysts forecast that Apogee Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Analyst Ratings Changes

APGE has been the topic of several analyst reports. Wedbush reissued an “outperform” rating and set a $87.00 target price on shares of Apogee Therapeutics in a report on Monday, May 13th. Bank of America initiated coverage on shares of Apogee Therapeutics in a research note on Friday, May 10th. They set a “buy” rating and a $80.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $78.50.

Institutional Investors Weigh In On Apogee Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Driehaus Capital Management LLC grew its holdings in shares of Apogee Therapeutics by 2.6% during the second quarter. Driehaus Capital Management LLC now owns 2,117,870 shares of the company’s stock worth $83,338,000 after purchasing an additional 54,107 shares during the last quarter. Perceptive Advisors LLC grew its position in shares of Apogee Therapeutics by 2.2% in the 2nd quarter. Perceptive Advisors LLC now owns 2,105,636 shares of the company’s stock valued at $82,857,000 after buying an additional 45,241 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Apogee Therapeutics by 60.7% in the first quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock valued at $124,173,000 after buying an additional 705,795 shares during the period. Wellington Management Group LLP raised its position in shares of Apogee Therapeutics by 0.3% during the fourth quarter. Wellington Management Group LLP now owns 1,591,478 shares of the company’s stock worth $44,358,000 after acquiring an additional 4,749 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Apogee Therapeutics by 51.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,170,327 shares of the company’s stock worth $77,770,000 after acquiring an additional 399,646 shares during the last quarter. 79.04% of the stock is owned by institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.